Categories: News

ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.

Access to Giving is a conference themed around investor education and advocacy with 50+ companies presenting, a keynote, three distinctive panels and 1×1 meetings.

ARCA is scheduled to present on Tuesday, July 13, 2021 at 2:00 PM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2744/41973.

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

About Access to Giving
Access to Giving is the first-of-its-kind virtual investor conference and will be held July 13th – 15th, 2021. Companies will have the opportunity to tell their story and conduct 1×1’s with qualified investors for charity. 100% of monies raised through donations for 1×1 meetings will be given to causes that are focused on financial literacy and financial education.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

Staff

Recent Posts

Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design

MILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP),…

5 hours ago

AffableBPM Graduates from 2025 Creative Destruction Lab (CDL) Program

Accelerating AI-Powered Automation for Healthcare Operations SEATTLE, June 16, 2025 /PRNewswire/ -- AffableBPM is proud…

5 hours ago

Waystar Appoints Aashima Gupta and Michael Roman to Board of Directors

New directors bring deep expertise in AI innovation, healthcare, and enterprise growth LEHI, Utah and…

11 hours ago

Occupational Health Market to Reach USD 8,453.96 million By 2032, Growing At An 6.50% CAGR – Credence Research

PUNE, India, June 16, 2025 /PRNewswire/ -- The global Occupational Health Market was valued at USD…

11 hours ago

AdventHealth Tampa first in region to perform colorectal surgery using da Vinci SP robot

TAMPA, Fla., June 16, 2025 /PRNewswire/ -- AdventHealth Tampa is now the first hospital in…

11 hours ago

AARP Services Announces New AARP Member Benefits Launching This Summer

WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the…

11 hours ago